Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Year of publication
- 2021 (8) (remove)
Document Type
- Journal article (8)
Language
- English (8)
Keywords
- hypercortisolism (2)
- ACTH (1)
- CTNNB1 (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- EMT (1)
- FGF-pathway (1)
- FGFR (1)
- NR3C1 (1)
- RNA Expression (1)
- RNAScope (1)
- USP8 (1)
- adjuvant treatment (1)
- adrenocortical cancer (1)
- adrenocortical carcinoma (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- bioinformatic clustering (1)
- biomarker (1)
- biomarker prediction (1)
- cardiovascular diseases (1)
- chronotype (1)
- circadian rhythms (1)
- cortisol (1)
- cortisol-producing adenoma (1)
- epidemiology (1)
- epithelial markers (1)
- genetic analysis (1)
- glucocorticoid excess (1)
- in silico analysis (1)
- machine learning (1)
- menopause (1)
- mesenchymal markers (1)
- miR-182-5p (1)
- miR-183 cluster (1)
- miRNA (1)
- mitotane (1)
- mortality (1)
- normal adrenal glands (1)
- obesity (1)
- paraganglioma (1)
- patient survival (1)
- pheochromocytoma (1)
- recurrence (1)
- recurrence free survival (1)
- recurrence-free survival (1)
- surveillance (1)
- timing (1)
- type 2 diabetes (1)
- unsupervised clustering (1)
Institute
- Medizinische Klinik und Poliklinik I (8)
- Pathologisches Institut (4)
- Center for Computational and Theoretical Biology (1)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
No studies have carried out an extensive analysis of the possible association between non-syndromic pheochromocytomas and paragangliomas (PPGLs) and other malignancies. To assess >the risk of additional malignancy in PPGL, we retrospectively evaluated 741 patients with PPGLs followed-up in twelve referral centers in Italy. Incidence of second malignant tumors was compared between this cohort and Italian patients with two subsequent malignancies. Among our patients, 95 (12.8%) developed a second malignant tumor, which were mainly prostate, colorectal and lung/bronchial cancers in males, breast cancer, differentiated thyroid cancer and melanoma in females. The standardized incidence ratio was 9.59 (95% CI 5.46–15.71) in males and 13.21 (95% CI 7.52–21.63) in females. At multivariable analysis, the risk of developing a second malignant tumor increased with age at diagnosis (HR 2.50, 95% CI 1.15–5.44, p = 0.021 for 50–59 vs. <50-year category; HR 3.46, 95% CI 1.67–7.15, p < 0.001 for >60- vs. <50-year). In patients with available genetic evaluation, a positive genetic test was inversely associated with the risk of developing a second tumor (HR 0.25, 95% CI 0.10–0.63, p = 0.003). In conclusion, PPGLs patients have higher incidence of additional malignant tumors compared to the general population who had a first malignancy, which could have an impact on the surveillance strategy.